BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 25412106)

  • 1. Adoptive immunotherapy of cytokine-induced killer cell therapy in the treatment of non-small cell lung cancer.
    Wang M; Cao JX; Pan JH; Liu YS; Xu BL; Li D; Zhang XY; Li JL; Liu JL; Wang HB; Wang ZX
    PLoS One; 2014; 9(11):e112662. PubMed ID: 25412106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy and safety of CIK plus radiotherapy for lung cancer: A meta-analysis of 16 randomized controlled trials.
    Xiao Z; Wang CQ; Zhou MH; Li NN; Liu SY; He YJ; Wang YZ; Feng JH; Yao XS; Chen L; Ma B; Yu S; Zeng XT; Li CW; Ding J
    Int Immunopharmacol; 2018 Aug; 61():363-375. PubMed ID: 29945024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of the number and interval of treatment cycles on cytokine-induced killer cells and their adjuvant therapeutic effects in advanced non-small-cell lung cancer (NSCLC).
    Gu Y; Lv H; Zhao J; Li Q; Mu G; Li J; Wuyang J; Lou G; Wang R; Zhang Y; Huang X
    Int Immunopharmacol; 2017 Sep; 50():263-269. PubMed ID: 28711032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients' preference-based study (PPPS).
    Zhao Y; Qiao G; Wang X; Song Y; Zhou X; Jiang N; Zhou L; Huang H; Zhao J; Morse MA; Hobeika A; Ren J; Lyerly HK
    Clin Transl Oncol; 2019 Jun; 21(6):721-728. PubMed ID: 30374838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of chemotherapy with cytokine-induced killer cells in non-small cell lung cancer: A systematic review and meta-analysis of 32 randomized controlled trials.
    Xiao Z; Wang CQ; Feng JH; Zhou MH; Wang YZ; Li NN; Sun YP; Liu SY; Yao XS; Li CW; Ma B; Ding J; Chen L
    Cytotherapy; 2019 Feb; 21(2):125-147. PubMed ID: 30554868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autologous cytokine-induced killer cell therapy in lung cancer patients: a retrospective study.
    Zhang J; Zhu L; Du H; He X; Yin Y; Gu Y; Liu L; Lu K; Guo R; Liu P; Shu Y
    Biomed Pharmacother; 2015 Mar; 70():248-52. PubMed ID: 25776508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Antitumor Immunity and Tumor Responses of Chemotherapy with or without DC-CIK for Non-Small-Cell Lung Cancer in China: A Meta-Analysis of 28 Randomized Controlled Trials.
    Xiao Z; Wang CQ; Zhou MH; Li NN; Sun YP; Wang YZ; Liu SY; Yu HS; Li CW; Zeng XT; Chen L; Yao XS; Feng JH
    J Immunol Res; 2018; 2018():9081938. PubMed ID: 30648123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokine-induced killer cells/dendritic cells-cytokine induced killer cells immunotherapy combined with chemotherapy for treatment of colorectal cancer in China: a meta-analysis of 29 trials involving 2,610 patients.
    Zhang L; Mu Y; Zhang A; Xie J; Chen S; Xu F; Wang W; Zhang Y; Ren S; Zhou C
    Oncotarget; 2017 Jul; 8(28):45164-45177. PubMed ID: 28404886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant chemotherapy with sequential cytokine-induced killer (CIK) cells in stage IB non-small cell lung cancer.
    Li DP; Li W; Feng J; Chen K; Tao M
    Oncol Res; 2015; 22(2):67-74. PubMed ID: 25706393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients.
    Yang L; Ren B; Li H; Yu J; Cao S; Hao X; Ren X
    Cancer Immunol Immunother; 2013 Jan; 62(1):65-73. PubMed ID: 22744010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased cycles of DC/CIK immunotherapy decreases frequency of Tregs in patients with resected NSCLC.
    Song H; Liu S; Zhao Z; Sun W; Wei X; Ma X; Zhao P; Gao D
    Int Immunopharmacol; 2017 Nov; 52():197-202. PubMed ID: 28941416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer.
    Wu C; Jiang J; Shi L; Xu N
    Anticancer Res; 2008; 28(6B):3997-4002. PubMed ID: 19192663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profiling the dynamic expression of checkpoint molecules on cytokine-induced killer cells from non-small-cell lung cancer patients.
    Zhang L; Wang J; Wei F; Wang K; Sun Q; Yang F; Jin H; Zheng Y; Zhao H; Wang L; Yu W; Zhang X; An Y; Yang L; Zhang X; Ren X
    Oncotarget; 2016 Jul; 7(28):43604-43615. PubMed ID: 27283895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of chemotherapy combined with cytokine-induced killer cell /dendritic cell-cytokine-induced killer cell therapy for treatment of gastric cancer in China: A systematic review and meta-analysis.
    Mu Y; Zhou CH; Chen SF; Ding J; Zhang YX; Yang YP; Wang WH
    Cytotherapy; 2016 Sep; 18(9):1162-77. PubMed ID: 27421742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cell immunotherapy combined with cytokine-induced killer cells promotes skewing toward Th2 cytokine profile in patients with metastatic non-small cell lung cancer.
    Zhao P; Bu X; Wei X; Sun W; Xie X; Li C; Guo Q; Zhu D; Wei X; Gao D
    Int Immunopharmacol; 2015 Apr; 25(2):450-6. PubMed ID: 25698555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models.
    Shi S; Wang R; Chen Y; Song H; Chen L; Huang G
    PLoS One; 2013; 8(6):e65757. PubMed ID: 23799045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant cytokine-induced killer cell immunotherapy improves long-term survival in patients with stage I-II non-small cell lung cancer after curative surgery.
    Huang J; Zhao X; Zhang Z; Yang S; Chen X; Shen C; Wang L; Qi Y; Zhang Y
    Cytotherapy; 2023 Feb; 25(2):202-209. PubMed ID: 36379882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of dendritic cells co-cultured with cytokine-induced killer cells immunotherapy for non-small-cell lung cancer.
    Wang S; Wang Z
    Int Immunopharmacol; 2015 Sep; 28(1):22-8. PubMed ID: 26013109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of cord blood-derived cytokine-induced killer cells in treatment of patients with malignancies.
    Zhang Z; Wang L; Luo Z; Zhao X; Huang J; Li H; Yang S; Zhao X; Zhang L; Li L; Wang F; Huang L; Zhang Y
    Cytotherapy; 2015 Aug; 17(8):1130-8. PubMed ID: 25963952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery.
    Li H; Wang C; Yu J; Cao S; Wei F; Zhang W; Han Y; Ren XB
    Cytotherapy; 2009; 11(8):1076-83. PubMed ID: 19929470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.